EIF4EBP1 and ovarian carcinoma: We confirmed that BEZ235 treatment for 6 h effectively inhibited activities of PI3K/mTOR effectors as assessed by reduced p-AKT S473, p-S6 and p-4E-BP1 levels compared with control treatment (Figure 6a), whereas Bay 65–1942 treatment consistently reduced CXCL1, CXCL2 and CXCL8 mRNA levels in all three ovarian cancer cell lines tested (Figure 6b).